Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Lepodisiran is being developed by biotech giant Eli Lilly & Co. (LLY), a stock that’s in my model portfolio. Here’s the tale of this new drug…how it could help millions of heart-ailment sufferers…and ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

Eli Lilly reports 94% Lp(a) reduction with lepodisiran in Phase 2 trials, targeting inherited heart disease risk.

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesis of lipoprotein(a), are unknown. We randomly assigned participants in a 1:2:2:2:2 ...

A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by at least 94 per cent. Lepodisiran, developed by Eli Lilly, has shown promising results in reducing ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...